(Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...
Colossal Biosciences raises $200M in Series C funding led by TWG Global, advancing its innovative de-extinction projects and ...
Caribou has initiated the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial designed to evaluate a single infusion of CB-010 in adult patients with LN and ERL. CB-011, a ...
Analyst Yanan Zhu from Wells Fargo maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report) and keeping the price target at ...
Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.
The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...
3don MSN
Colossal Biosciences, which aims to revive extinct species, announced it has raised an additional $200 million. Critics say ...
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs ...
Colossal BioSciences has raised $200 million in a new round of funding to bring back extinct species like the woolly mammoth.
Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...
Hosted on MSN5d
Genetic tweak to drug-making cells resolves a decades-old challenge in biomanufacturingThe research, "Multiplex genome editing eliminates the Warburg Effect without impacting ... they mapped out a network of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback